4.96
-0.06 (-1.20%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | ImageneBio, Inc. | Mixed | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.50 |
|
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 917,692 |
| Cable Car Capital, Lp | 30 Jun 2026 | 781,599 |
| Omega Fund Management, Llc | 30 Jun 2026 | 455,361 |
| Rtw Investments, Lp | 30 Jun 2026 | 334,445 |
| Trails Edge Capital Partners, Lp | 30 Jun 2026 | 282,004 |
| Bml Capital Management, Llc | 30 Jun 2026 | 200,730 |
| Monashee Investment Management Llc | 30 Jun 2026 | 192,344 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2026 | 66,666 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |